The earnings per share (EPS) of Beximco Limited and Beximco Pharmaceuticals saw a year-on-year decrease in the October-December quarter of 2022-23 fiscal year, mainly due to price hikes of raw materials, according to their financial statements.
The conglomerate's EPS stood at Tk3.60 in the second quarter of FY23, which is 19% lower than the same time of the previous year.
At the end of the first half, its EPS stood at Tk7.35, which was Tk8.48 a year ago.
Earlier, it earned a record profit of Tk1,255 crore in FY22 owing to its diversified business in Covid-19 treatment equipment.
Currently, its shares are stuck on the floor price at Tk115.60 each at the Dhaka Stock Exchange (DSE).
Beximco Pharmaceuticals, a leading drug maker in the country, registered quarterly EPS of Tk2.77 in October-December last year, a 28% down from Tk3.84 in the same quarter the previous year.
However, its revenue grew by 16% to Tk898 crore in the second quarter of FY23.
Its EPS stood at Tk6.02 in the first half of FY23, which was Tk7.12 a year ago.
At the end of the first half, its total revenue stood at Tk1,968 crore, a 16% increase from the previous year.
In FY21, it earned a record profit of Tk512 crore from supplying Covid-19 vaccines and paid a 35% cash dividend to its shareholders which is also the highest in its history.
Its share price fell by 1.01% to Tk146.70 each on Sunday at the DSE.